PemetrexedDisodiumSaltHeptahydrate , 99% , 357166-29-1

Synonym(s):
Pemetrexed disodium heptahydrate

CAS NO.：357166-29-1

Empirical Formula: C20H19N5Na2O6.7(H2O)

Molecular Weight: 597

MDL number: MFCD09029394

EINECS: 639-569-0

PRODUCT Properties

• storage temp.: 2-8°C
• solubility: H2O: soluble30mg/mL, clear
• form: powder
• color: white to beige
• Water Solubility: H2O: 30mg/mL, clear
• Stability: Stable for 1 year as supplied. Solutions in distilled water may be stored at -20° for up to 31month.
• InChIKey: AEZRDYKQLPDYEH-YTCXBBKHNA-N
• SMILES: C(C1=CNC2NC(N)=NC(=O)C1=2)CC1C=CC(C(=O)N[C@H](C(=O)O)CCC(=O)O)=CC=1.[NaH].O |&1:20,r|

Description and Uses

Pemetrexed Disodium Heptahydrate(357166-29-1) is a multi-targeted antifolate with antitumor activity. Its formal name is N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt hydrate. It potently inhibits folate-dependent enzymes involved in both purine and pyrimidine synthesis including thymidylate synthase (Ki?= 109 nM), dihydrofolate reductase (Ki?= 7 nM), glycinamide ribonucleotide formyltransferase (Ki?= 9.3 μM), and aminoimidazole carboxamide ribonucleotide formyltransferase (Ki?= 3.6 μM). It is a clinically useful anticancer agent. Indirectly activates the metabolic kinase AMPK and consequently influences the mTORC1 pathway in human carcinomas. Activation of AMPK is associated with pemetrexed resistance. Induces G0/G1-phase cell cycle arrest in esophageal squamous cell carcinoma cells.

Pemetrexed Disodium Heptahydrate is an chemotherapy drug for the treatment of pleural mesothelioma and non-small cell lung cancer. Pemetrexed Disodium Heptahydrate exhibit inhibitory activities towards thymidylate synthase as well as other folate dependent enzymes.

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Danger
• Hazard statements: H315-H319-H341-H360FD-H372
• Precautionary statements: P202-P260-P264-P302+P352-P305+P351+P338-P308+P313
• Safety Statements: 24/25
• WGK Germany: 3
• HS Code: 29335990